MedPath

IMPROVE - improving anxiety treatments by modulating emotional memories prior to in vivo exposure: a multiple baseline study

Phase 2
Conditions
Social anxiety (anxiety in social situations)
10002861
Registration Number
NL-OMON53388
Lead Sponsor
niversiteit Utrecht
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
8
Inclusion Criteria

- Patients >=18 years of age
- Sufficient mastery of the Dutch language and ability to complete
questionnaires and understand informed consent information
- Meeting DSM-5 criteria for social anxiety disorder (assessed with
MINI-S-DSM-5).
- Stable medication for at least six weeks before starting participation in the
study and willingness by the patient and physician to keep the medication
stable during the study period. The use of sedating medication (e.g.
benzodiazepines) is no contraindication however, participants are strongly
advised not to use sedating medication prior to- or after treatment sessions
and subsequent days. The use of sedating medication will be registered
- Self-reported ability to refrain from alcohol or drugs 24 hours before and
after each session. General use of alcohol or drugs will be discouraged.

Exclusion Criteria

- Self-reported neurological disorder
- Acute or recent history of suicide attempts according to the (MINI-S-DSM-5)
section C
- Self-reported visual or auditory impairments that could hinder treatment
- Self-reported current psychological treatment for other DSM-5 disorders
- Being reluctant or unable to complete questionnaires online

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Primary outcomes are: 1. social anxiety symptoms. 2. Social avoidance<br /><br>symptoms. </p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Secondary outcomes are: Weekly social anxiety symptom severity. </p><br>
© Copyright 2025. All Rights Reserved by MedPath